Evolus (NASDAQ:EOLS) Earns Buy Rating from Needham & Company LLC

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports. They currently have a $22.00 target price on the stock. Needham & Company LLC’s price target would indicate a potential upside of 53.31% from the company’s current price.

EOLS has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Wednesday. Barclays boosted their target price on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday.

Evolus Trading Up 0.1 %

Shares of EOLS opened at $14.35 on Wednesday. The stock’s 50-day moving average price is $12.72 and its 200 day moving average price is $14.08. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $908.66 million, a price-to-earnings ratio of -15.77 and a beta of 1.33. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82.

Institutional Investors Weigh In On Evolus

Several hedge funds have recently bought and sold shares of EOLS. Tri Locum Partners LP acquired a new position in shares of Evolus in the fourth quarter valued at $8,198,000. Gilder Gagnon Howe & Co. LLC raised its holdings in shares of Evolus by 287.2% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock worth $7,753,000 after buying an additional 520,859 shares in the last quarter. Caligan Partners LP lifted its holdings in shares of Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after acquiring an additional 498,900 shares during the last quarter. Allostery Investments LP bought a new stake in shares of Evolus during the fourth quarter worth $4,760,000. Finally, Altium Capital Management LLC grew its position in Evolus by 93.0% during the 4th quarter. Altium Capital Management LLC now owns 685,000 shares of the company’s stock worth $7,562,000 after acquiring an additional 330,000 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.